Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2010 4
2011 6
2012 15
2013 18
2014 27
2015 23
2016 18
2017 19
2018 9
2019 12
2020 9
2021 14
2022 11
2023 14
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Results by year

Filters applied: . Clear all
Page 1
FGF receptors: cancer biology and therapeutics.
Katoh M, Nakagama H. Katoh M, et al. Med Res Rev. 2014 Mar;34(2):280-300. doi: 10.1002/med.21288. Epub 2013 May 21. Med Res Rev. 2014. PMID: 23696246 Review.
Missense mutations of FGFR2 are found in endometrial uterine cancer and melanoma, and similar FGFR3 mutations in invasive bladder tumors, and FGFR4 mutations in rhabdomyosarcoma. Dovitinib, Ki23057, ponatinib, and AZD4547 are orally bioavailable FGFR inhibitors, which have …
Missense mutations of FGFR2 are found in endometrial uterine cancer and melanoma, and similar FGFR3 mutations in invasive bladder tumors, an …
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M. Katoh M. Int J Mol Med. 2016 Jul;38(1):3-15. doi: 10.3892/ijmm.2016.2620. Epub 2016 May 31. Int J Mol Med. 2016. PMID: 27245147 Free PMC article. Review.
BCR-FGFR1, CNTRL-FGFR1, CUX1-FGFR1, FGFR1OP-FGFR1, MYO18A-FGFR1 and ZMYM2-FGFR1 fusions in myeloproliferative neoplasms are non-receptor-type FGFR kinases, whereas FGFR1-TACC1, FGFR2-AFF3, FGFR2-BICC1, FGFR2-PPHLN1, FGFR3-BAIAP2L1 and FGFR3-TACC3 fusions in solid tumors are trans …
BCR-FGFR1, CNTRL-FGFR1, CUX1-FGFR1, FGFR1OP-FGFR1, MYO18A-FGFR1 and ZMYM2-FGFR1 fusions in myeloproliferative neoplasms are non-receptor-typ …
Preformulation studies of dovitinib free base: Solubility, lipophilicity and stability.
Sripetch S, Ryzhakov A, Loftsson T. Sripetch S, et al. Int J Pharm. 2022 May 10;619:121721. doi: 10.1016/j.ijpharm.2022.121721. Epub 2022 Apr 6. Int J Pharm. 2022. PMID: 35398252
Dovitinib free base has a poor water solubility leading to poor absorption. ...Aqueous solubility of dovitinib salt depended on the counterion. Lactic acid greatly increased the aqueous solubility of dovitinib. ...
Dovitinib free base has a poor water solubility leading to poor absorption. ...Aqueous solubility of dovitinib salt depended o …
DNA-Encoded Library Screening To Inform Design of a Ribonuclease Targeting Chimera (RiboTAC).
Meyer SM, Tanaka T, Zanon PRA, Baisden JT, Abegg D, Yang X, Akahori Y, Alshakarchi Z, Cameron MD, Adibekian A, Disney MD. Meyer SM, et al. J Am Chem Soc. 2022 Nov 23;144(46):21096-21102. doi: 10.1021/jacs.2c07217. Epub 2022 Nov 7. J Am Chem Soc. 2022. PMID: 36342850 Free PMC article.
This compound was incorporated into the design of a next-generation RiboTAC that targeted the microRNA-21 (miR-21) precursor and alleviated a miR-21-associated cellular phenotype in triple-negative breast cancer cells. The RNA-binding module in the RiboTAC is Dovitinib, a …
This compound was incorporated into the design of a next-generation RiboTAC that targeted the microRNA-21 (miR-21) precursor and alleviated …
Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-γ signalling.
Cao LL, Lu H, Soutto M, Bhat N, Chen Z, Peng D, Gomaa A, Wang JB, Xie JW, Li P, Zheng CH, Nomura S, Datta J, Merchant N, Chen ZB, Villarino A, Zaika A, Huang CM, El-Rifai W. Cao LL, et al. Gut. 2023 Nov;72(11):2038-2050. doi: 10.1136/gutjnl-2022-329134. Epub 2023 Jul 4. Gut. 2023. PMID: 37402563
Our analysis further identified a panel of RTKs as potential druggable targets in the immune desert-type GC. Dovitinib, an inhibitor of multiple RTKs, strikingly repressed EMT programming in mesenchymal-like immune desert syngeneic GC models. Dovitinib activated the …
Our analysis further identified a panel of RTKs as potential druggable targets in the immune desert-type GC. Dovitinib, an inhibitor …
Targeted FGFR/VEGFR/PDGFR inhibition with dovitinib enhances the effects of nab-paclitaxel in preclinical gastric cancer models.
Crawford K, Bontrager E, Schwarz MA, Chaturvedi A, Lee DD, Md Sazzad H, von Holzen U, Zhang C, Schwarz RE, Awasthi N. Crawford K, et al. Cancer Biol Ther. 2021 Dec 2;22(10-12):619-629. doi: 10.1080/15384047.2021.2011642. Epub 2021 Dec 9. Cancer Biol Ther. 2021. PMID: 34882068 Free PMC article.
Based on the antimitotic, antistromal and EPR effects of nab-paclitaxel, we investigated augmentation of nab-paclitaxel response by dovitinib in multiple GAC preclinical models. In MKN-45 subcutaneous xenografts, inhibition in tumor growth by nab-paclitaxel and dovitini …
Based on the antimitotic, antistromal and EPR effects of nab-paclitaxel, we investigated augmentation of nab-paclitaxel response by dovit …
Metastatic pheochromocytomas and paragangliomas: where are we?
Prinzi N, Corti F, Torchio M, Niger M, Antista M, Pagani F, Beninato T, Pulice I, Rossi RE, Coppa J, Cascella T, Giacomelli L, Di Bartolomeo M, Milione M, de Braud F, Pusceddu S. Prinzi N, et al. Tumori. 2022 Dec;108(6):526-540. doi: 10.1177/03008916221078621. Epub 2022 May 20. Tumori. 2022. PMID: 35593402 Review.
The efficacy of sunitinib has been shown in observational studies, and pembrolizumab has been evaluated in phase II clinical studies, while other agents investigated in this setting are anti-angiogenic drugs cabozantinib, dovitinib, axitinib and lenvatinib. As these agents …
The efficacy of sunitinib has been shown in observational studies, and pembrolizumab has been evaluated in phase II clinical studies, while …
Dovitinib induces mitotic defects and activates the G2 DNA damage checkpoint.
Man WY, Mak JP, Poon RY. Man WY, et al. J Cell Mol Med. 2014 Jan;18(1):143-55. doi: 10.1111/jcmm.12176. Epub 2013 Nov 18. J Cell Mol Med. 2014. PMID: 24238094 Free PMC article.
Higher concentrations of Dovitinib induced a G2 arrest similar to the G2 DNA damage checkpoint. In support of this, DNA damage was triggered by Dovitinib as revealed by gamma-H2AX and comet assays. The mitotic kinase CDK1 was found to be inactivated by phosphorylati …
Higher concentrations of Dovitinib induced a G2 arrest similar to the G2 DNA damage checkpoint. In support of this, DNA damage was tr …
A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors.
Knudsen S, Hansen A, Foegh M, Petersen S, Mekonnen H, Jia L, Shah P, Martin V, Frykman G, Pili R. Knudsen S, et al. PLoS One. 2023 Aug 30;18(8):e0290681. doi: 10.1371/journal.pone.0290681. eCollection 2023. PLoS One. 2023. PMID: 37647320 Free PMC article.
The drug response predictor (DRP) biomarker algorithm or DRP-Dovitinib is being developed as a companion diagnostic to dovitinib and was applied retrospectively. ...RESULTS: The DRP-Dovitinib divided the dovitinib treated RCC patients into two groups, …
The drug response predictor (DRP) biomarker algorithm or DRP-Dovitinib is being developed as a companion diagnostic to dovitinib …
Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
Tai WT, Cheng AL, Shiau CW, Liu CY, Ko CH, Lin MW, Chen PJ, Chen KF. Tai WT, et al. Mol Cancer Ther. 2012 Feb;11(2):452-63. doi: 10.1158/1535-7163.MCT-11-0412. Epub 2011 Dec 16. Mol Cancer Ther. 2012. PMID: 22180308
Ectopic expression of STAT3 abolished the apoptotic effect of dovitinib, indicating that STAT3 is indispensable in mediating the effect of dovitinib in HCC. ...Notably, dovitinib increased SHP-1 activity in HCC cells. Incubation of dovitinib with pure …
Ectopic expression of STAT3 abolished the apoptotic effect of dovitinib, indicating that STAT3 is indispensable in mediating the effe …
183 results